



an Open Access Journal by MDPI

## Innovative Approaches in Drug Design: The Pathway from Molecular Mechanisms to New Therapeutic Interventions

Guest Editors:

**Dr. Cristina Manuela Dragoi**

Department of Biochemistry,  
Faculty of Pharmacy, Carol Davila  
University of Medicine and  
Pharmacy, 020956 Bucharest,  
Romania

**Dr. Alina Crenguta Nicolae**

Faculty of Pharmacy, University  
of Medicine and Pharmacy “Carol  
Davila”, 020956 Bucharest,  
Romania

**Dr. Ion-Bogdan Dumitrescu**

Faculty of Pharmacy, University  
of Medicine and Pharmacy “Carol  
Davila”, 020956 Bucharest,  
Romania

Deadline for manuscript  
submissions:

**closed (20 January 2025)**

### Message from the Guest Editors

The field of drug design is undergoing a transformative phase characterized by the exploration of pioneering strategies that transcend traditional paradigms. At the heart of these innovative actions lies a deep understanding of the molecular foundations of diseases, coupled with the development of sophisticated tools and technologies which, informed by structural biology, computational chemistry, pharmacology, and bioinformatics, are aimed at manipulating these complex biological pathways. The elucidation of three-dimensional structures of relevant biomolecules at atomic resolution enables the precise targeting of specific molecular targets implicated in disease progression.

In this Special Issue, we welcome articles dealing with all aspects of drug design research, from basic to clinical studies, and invite scientists and drug specialists to publish their original research works, review articles, and communications on this wide health domain.



[mdpi.com/si/196343](https://mdpi.com/si/196343)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)